Individuals with anaplastic lymphoma kinase-positive non-small cell lung cancer who received ensartinib had 25.8 months median progression-free survival, compared with 12.7 months median PFS among those who were given crizotinib, study results show. "Ensartinib showed superior efficacy in the brain over crizotinib and represents a new first-line treatment option for patients with ALK-positive NSCLC," said researcher Dr. Leora Horn.
Ensartinib better than crizotinib in ALK-positive NSCLC
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.